Efficacy and tolerability of three topical acne treatments by body mass index: post hoc analysis including overweight and obese patients

References

• Bhate K, Williams HC. Epidemiology of acne vulgaris. Br J Dermatol. 2013;168(3):474–485.
   PubMed Web of Science ®Google Scholar
• Gallitano SM, Berson DS. How acne bumps cause the blues: the influence of acne vulgaris on self-esteem. Int J Womens Dermatol. 2018;4(1):12–17.
   PubMedGoogle Scholar
• Gieler U, Gieler T, Kupfer JP. Acne and quality of life – impact and management. J Eur Acad Dermatol Venereol. 2015;29(Suppl 4):12–14.
   PubMed Web of Science ®Google Scholar
• Gorelick J, Daniels SR, Kawata AK, et al. Acne-related quality of life among female adults of different races/ethnicities. J Dermatol Nurses Assoc. 2015;7(3):154–162.
   PubMedGoogle Scholar
• Mallon E, Newton JN, Klassen A, et al. The quality of life in acne: a comparison with general medical conditions using generic questionnaires. Br J Dermatol. 1999;140(4):672–676.
   PubMed Web of Science ®Google Scholar
• Nguyen CM, Beroukhim K, Danesh MJ, et al. The psychosocial impact of acne, vitiligo, and psoriasis: a review. Clin Cosmet Investig Dermatol. 2016;9:383–392.
   PubMed Web of Science ®Google Scholar
• Tanghetti EA, Kawata AK, Daniels SR, et al. Understanding the burden of adult female acne. J Clin Aesthet Dermatol. 2014;7(2):22–30.
   PubMedGoogle Scholar
• Goulden V, Stables GI, Cunliffe WJ. Prevalence of facial acne in adults. J Am Acad Dermatol. 1999;41(4):577–580.
   PubMed Web of Science ®Google Scholar
• Perkins AC, Cheng CE, Hillebrand GG, et al. Comparison of the epidemiology of acne vulgaris among Caucasian, Asian, Continental Indian and African American Women. J Eur Acad Dermatol Venereol. 2011;25(9):1054–1060.
   PubMed Web of Science ®Google Scholar
• Heng AHS, Chew FT. Systematic review of the epidemiology of acne vulgaris. Sci Rep. 2020;10(1):5754.
   PubMed Web of Science ®Google Scholar
• Anaba LE, Ogunbiyi OA, George OA. Adolescent facial acne vulgaris and body mass index: Any relationship? West Afr J Med. 2019;36(2):129–132.
   PubMedGoogle Scholar
• Halvorsen JA, Vleugels RA, Bjertness E, et al. A population-based study of acne and body mass index in adolescents. Arch Dermatol. 2012;148(1):131–132.
   PubMedGoogle Scholar
• Snast I, Dalal A, Twig G, et al. Acne and obesity: a nationwide study of 600,404 adolescents. J Am Acad Dermatol. 2019;81(3):723–729.
   PubMed Web of Science ®Google Scholar
• Karciauskiene J, Valiukeviciene S, Gollnick H, et al. The prevalence and risk factors of adolescent acne among schoolchildren in Lithuania: a cross-sectional study. J Eur Acad Dermatol Venereol. 2014;28(6):733–740.
   PubMed Web of Science ®Google Scholar
• Sas K, Reich A. High body mass index is a risk factor for acne severity in adolescents: a preliminary report. Acta Dermatovenerol Croat. 2019;27(2):81–85.
   PubMed Web of Science ®Google Scholar
• Lu PH, Hsu CH. Body mass index is negatively associated with acne lesion counts in Taiwanese Women with post-adolescent acne. J Eur Acad Dermatol Venereol. 2015;29(10):2046–2050.
   PubMed Web of Science ®Google Scholar
• Tsai MC, Chen W, Cheng YW, et al. Higher body mass index is a significant risk factor for acne formation in schoolchildren. Eur J Dermatol. 2006;16(3):251–253.
   PubMed Web of Science ®Google Scholar
• Borgia F, Cannavo S, Guarneri F, et al. Correlation between endocrinological parameters and acne severity in adult women. Acta Derm Venereol. 2004;84(3):201–204.
   PubMed Web of Science ®Google Scholar
• Bruni V, Capozzi A, Lello S. The role of genetics, epigenetics and lifestyle in polycystic ovary syndrome development: the state of the art. Reprod Sci. 2022;29(3):668–679.
   PubMed Web of Science ®Google Scholar
• Khunger N, Mehrotra K. Menopausal acne – challenges and solutions. Int J Womens Health. 2019;11:555–567.
   PubMed Web of Science ®Google Scholar
• Makrantonaki E, Ganceviciene R, Zouboulis C. An update on the role of the sebaceous gland in the pathogenesis of acne. Dermatoendocrinol. 2011;3(1):41–49.
   PubMedGoogle Scholar
• Tanghetti EA, Werschler WP, Lain T, et al. Tazarotene 0.045% lotion for once-daily treatment of moderate-to-severe acne vulgaris: results from two phase 3 trials. J Drugs Dermatol. 2020;19(1):70–77.
   Google Scholar
• Dreno B. What is new in the pathophysiology of acne, an overview. J Eur Acad Dermatol Venereol. 2017;31(Suppl 5):8–12.
   PubMed Web of Science ®Google Scholar
• Tan JKL, Stein Gold LF, Alexis AF, et al. Current concepts in acne pathogenesis: pathways to inflammation. Semin Cutan Med Surg. 2018;37(3S):S60–S2.
   PubMed Web of Science ®Google Scholar
• Austin J, Marks D. Hormonal regulators of appetite. Int J Pediatr Endocrinol. 2009;2009:141753.
   PubMedGoogle Scholar
• Kullmann S, Valenta V, Wagner R, et al. Brain insulin sensitivity is linked to adiposity and body fat distribution. Nat Commun. 2020;11(1):1841.
   PubMed Web of Science ®Google Scholar
• Nowicki M, Bryc W, Kokot F. Hormonal regulation of appetite and body mass in patients with advanced prostate cancer treated with combined androgen blockade. J Endocrinol Invest. 2001;24(1):31–36.
   PubMed Web of Science ®Google Scholar
• Vargas E, Joy NV, Carrillo Sepulveda MA. Biochemistry, insulin metabolic effects. Treasure Island (FL): Statpearls; 2021.
   Google Scholar
• Kahn BB, Flier JS. Obesity and insulin resistance. J Clin Invest. 2000;106(4):473–481.
   PubMed Web of Science ®Google Scholar
• Pasquali R. Obesity and androgens: facts and perspectives. Fertil Steril. 2006;85(5):1319–1340.
   PubMed Web of Science ®Google Scholar
• Bourne S, Jacobs A. Observations on acne, seborrhoea, and obesity. Br Med J. 1956;1(4978):1268–1270.
   PubMedGoogle Scholar
• Di Landro A, Cazzaniga S, Parazzini F, et al. Family history, body mass index, selected dietary factors, menstrual history, and risk of moderate to severe acne in adolescents and young adults. J Am Acad Dermatol. 2012;67(6):1129–1135.
   PubMed Web of Science ®Google Scholar
• Hales CM, Carroll MD, Fryar CD, et al. Prevalence of obesity and severe obesity among adults: United States, 2017–2018. Hyattsville, MD: National center for health statistics; 2020.
   Google Scholar
• Kolotkin RL, Andersen JR. A systematic review of reviews: exploring the relationship between obesity, weight loss and health-related quality of life. Clin Obes. 2017;7(5):273–289.
   PubMed Web of Science ®Google Scholar
• Yang L, Colditz GA. Prevalence of overweight and obesity in the United States, 2007-2012. JAMA Intern Med. 2015;175(8):1412–1413.
   PubMed Web of Science ®Google Scholar
• Pariser DM, Rich P, Cook-Bolden FE, et al. An aqueous gel fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 3.75% for the once-daily treatment of moderate to severe acne vulgaris. J Drugs Dermatol. 2014;13(9):1083–1089.
   PubMed Web of Science ®Google Scholar
• Tyring SK, Kircik LH, Pariser DM, et al. Novel tretinoin 0.05% lotion for the once-daily treatment of moderate-to-severe acne vulgaris: assessment of efficacy and safety in patients aged 9 years and older. J Drugs Dermatol. 2018;17(10):1084–1091.
   PubMed Web of Science ®Google Scholar
• Martin AR, Lookingbill DP, Botek A, et al. Health-related quality of life among patients with facial acne – assessment of a new acne-specific questionnaire. Clin Exp Dermatol. 2001;26(5):380–385.
   PubMed Web of Science ®Google Scholar
• Harper JC. The efficacy and tolerability of a fixed combination clindamycin (1.2%) and benzoyl peroxide (3.75%) aqueous gel in patients with facial acne vulgaris: gender as a clinically relevant outcome variable. J Drugs Dermatol. 2015;14(4):381–384.
   PubMed Web of Science ®Google Scholar
• Cook-Bolden FE. Efficacy and tolerability of a fixed combination of clindamycin phosphate (1.2%) and benzoyl peroxide (3.75%) aqueous gel in moderate or severe adolescent acne vulgaris. J Clin Aesthet Dermatol. 2015;8(5):28–32.
   PubMedGoogle Scholar
• Zeichner JA. The efficacy and tolerability of a fixed combination clindamycin (1.2%) and benzoyl peroxide (3.75%) aqueous gel in adult female patients with facial acne vulgaris. J Clin Aesthet Dermatol. 2015;8(4):21–25.
   PubMedGoogle Scholar
• Gold MH, Korotzer A. Sub-group analyses from a trial of a fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 3.75% gel for the treatment of moderate-to-severe acne vulgaris. J Clin Aesthet Dermatol. 2015;8(12):22–26.
   Google Scholar
• Alexis AF, Cook-Bolden F, Lin T. Treatment of moderate-to-severe acne vulgaris in a Hispanic population: a post-hoc analysis of the efficacy and tolerability of clindamycin 1.2%/benzoyl peroxide 3.75% gel. J Clin Aesthet Dermatol. 2017;10(6):36–43.
   PubMedGoogle Scholar
• Kircik LH, Baldwin H, Lain E, et al. Novel tretinoin 0.05% lotion for the once-daily treatment of moderate-to-severe acne vulgaris in an adult and adolescent female population. J Drugs Dermatol. 2019;18(2):178–188.
   PubMed Web of Science ®Google Scholar
• Han G, Armstrong AW, Desai SR, et al. Novel tretinoin 0.05% lotion for the once-daily treatment of moderate-to-severe acne vulgaris in an Asian Population. J Drugs Dermatol. 2019;18(9):910–916.
   PubMed Web of Science ®Google Scholar
• Cook-Bolden FE, Weinkle SH, Guenin E, et al. Novel tretinoin 0.05% lotion for once-daily treatment of moderate-to-severe acne vulgaris in a Hispanic Population. J Drugs Dermatol. 2019;18(1):32–38.
   PubMed Web of Science ®Google Scholar
• Stein Gold L, Pariser, DM, Guenin, E.. Tretinoin 0.05% lotion for the once-daily treatment of moderate and severe acne vulgaris in females: effect of age on efficacy and tolerability. J Drugs Dermatol. 2019;18(12):1218–1225.
   PubMed Web of Science ®Google Scholar
• Eichenfield LF, Sugarman JL, Guenin E, et al. Novel tretinoin 0.05% lotion for the once-daily treatment of moderate-to-severe acne vulgaris in a preadolescent population. Pediatr Dermatol. 2019;36(2):193–199.
   PubMed Web of Science ®Google Scholar
• Lain E, Day D, Harper J, et al. E. Tretinoin 0.05% lotion for the once-daily treatment of moderate-to-severe acne vulgaris: impact of gender and race on efficacy and safety. J Drugs Dermatol. 2019;18(11):1128–1138.
   PubMed Web of Science ®Google Scholar
• Bhatia ND, Werschler WP, Cook-Bolden FE, et al. Tolerability of tretinoin lotion 0.05% for moderate to severe acne vulgaris: a post hoc analysis in a black population. Cutis. 2020;106(1):45–50;e1.
   PubMed Web of Science ®Google Scholar
• Bhatia N, Weiss JS, Sadick N, et al. Novel polymeric tazarotene 0.045% lotion for moderate-to-severe acne: pooled phase 3 analysis by race/ethnicity. J Drugs Dermatol. 2020;19(7):727–734.
   Google Scholar
• Cook-Bolden FE, Gold MH, Guenin E. Tazarotene 0.045% lotion for the once-daily treatment of moderate-to-severe acne vulgaris in adult males. J Drugs Dermatol. 2020;19(1):78–85.
   Google Scholar
• Kircik LH, Gold LS, Beer K, et al. Once-daily polymeric tazarotene 0.045% lotion for moderate-to-severe acne: pooled phase 3 analysis by sex. J Drugs Dermatol. 2020;19(8):777–783.
   Google Scholar
• Eichenfield LF, Tanghetti EA, Guenin E, et al. New polymeric once-daily tazarotene 0.045% lotion formulation for moderate-to-severe acne: pooled phase 3 pediatric analysis. J Drugs Dermatol. 2020;19(6):602–610.
   PubMed Web of Science ®Google Scholar
• Green LJ, Del Rosso JQ, Tanghetti EA, et al. Tazarotene 0.045% lotion for moderate-to-severe acne patients: pooled phase 3 analysis by age and sex. J Drugs Dermatol. 2021;20(6):608–615.
   PubMed Web of Science ®Google Scholar
• Skroza N, Tolino E, Mambrin A, et al. Adult acne versus adolescent acne: a retrospective study of 1,167 patients. J Clin Aesthet Dermatol. 2018;11(1):21–25.
   PubMedGoogle Scholar
• Callender VD, Alexis AF, Daniels SR, et al. Racial differences in clinical characteristics, perceptions and behaviors, and psychosocial impact of adult female acne. J Clin Aesthet Dermatol. 2014;7(7):19–31.
   PubMedGoogle Scholar
• Kircik LH, Lain E, Gold M, et al. Effects of tazarotene 0.045% lotion on quality of life in patients with moderate-to-severe acne. J Drugs Dermatol. 2020;19(11):1086–1092.
   PubMed Web of Science ®Google Scholar
• Kircik LH, Draelos ZD, Berson DS. Polymeric emulsion technology applied to tretinoin. J Drugs Dermatol. 2019;18(4):S148–S54.
   PubMed Web of Science ®Google Scholar
• Tanghetti EA, Stein Gold L, Del Rosso JQ, et al. Optimized formulation for topical application of a fixed combination halobetasol/tazarotene lotion using polymeric emulsion technology. J Dermatolog Treat. 2021;32(4):391–398.
   PubMed Web of Science ®Google Scholar
• Tanghetti EA, Kircik LH, Green LJ, et al. 2, Multicenter, double-blind, randomized, vehicle-controlled clinical study to compare the safety and efficacy of a novel tazarotene 0.045% lotion and tazarotene 0.1% cream in the treatment of moderate-to-severe acne vulgaris. J Drugs Dermatol. 2019;18(6):542.
   PubMed Web of Science ®Google Scholar
• Draelos ZD, Tanghetti E, Stein Gold L, et al. Tazarotene 0.045% lotion for acne: formulation, application characteristics, and clinical efficacy and safety. J of Skin. 2021;5(6):s69.
   Google Scholar